Status:
COMPLETED
Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Forest Laboratories
Conditions:
Depressive Disorder, Major
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether taking the medication memantine reduces impairment of memory and attention associated with electroconvulsive therapy.
Detailed Description
The primary objective of this study is to determine whether the novel NMDA antagonist memantine, FDA approved for use in moderate to severe alzheimers dementia, may reduce the neurocognitive deficits ...
Eligibility Criteria
Inclusion
- :
- Meets DSM-IV criteria for Major Depressive Disorder
- 18 to 75 years of age and able to provide legal consent
- Referred to Stanford ECT service by treating physician for unilateral electroconvulsive therapy with inpatient hospitalization
- Competed process for consenting to the clinical use of ECT according to California State law
- Females of childbearing potential will be required to use a double-barrier method of contraception, which includes foam and either condom and diaphragm, IUD, and/or implant during study.\

Exclusion
- Treatment with ECT in the 6 months prior to screening
- Meets criteria for drug or alcohol abuse or dependence in the 6 months prior to screening
- Use of alcohol or illegal drugs within seven days of randomization or during study. Patients may be excluded for use during a period greater than 7 days, per study physician's discretion
- Presence of unstable or untreated cardiovascular disease, hypertension, or endocrine disorder as determined by the investigator
- use of antipsychotic, antidepressant, or other prescription medications unless dose is stable for at least 7 days prior to randomization.
- Use of any investigational treatment within 30 days of randomization
- Previous allergic reaction to memantine or drugs of similar chemical structure.
- Women who are pregnant or breastfeeding are not advised to participate in the research study
- Any neurological disorder or organic brain condition that would confound neurocognitive testing
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00186498
Start Date
February 1 2004
End Date
February 1 2008
Last Update
September 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305